Invent Medic’s product Efemia bladder support approved for subscription with reimbursement in the Netherlands. 

Invent Medic announces that the company’s first product Efemia bladder support has been approved for subscription with reimbursement in the Netherlands from February 2020. Efemia has already received an equivalent approval in Norway, and the product is also approved for subscription in three Swedish healthcare regions (of which framework agreement in one region) and 23 municipalities in Denmark.

Efemia was introduced in the Netherlands by the distributor Pelvitec in November 2019 at a conference for nurses specialized in stress urinary incontinence (SUI). The product is available for purchase in the country from Q1 2020.

Pelvitec’s continued work to establish the product in the Netherlands will now be facilitated as physicians, specialized nurses and pelvic floor therapists are able to subscribe the product to their patients. Most patients are covered by the country’s system for reimbursement, with some variations due to their insurance solutions, and the system covers 100 % of the cost of Efemia.

“It is satisfying that Efemia has been approved for subscription with reimbursement in yet another European market. The product will now become more accessible for women in the Netherlands seeking a simple, effective and non-surgical solution for SUI, and they do not have to worry about the cost, says Invent Medic’s CEO Karin Bryder.

In March 2020, Invent Medic will participate at EAU20, the biggest urological event in Europe. Invent Medic will be participating together with its distributors AGH (UK), Arteriomed (Germany) and Pelvitec (the Netherlands and Belgium).

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.



wkr0006.pdf